Infigratinib Gets FDA Priority Review for Achondroplasia
FDA accepts the oral infigratinib NDA for achondroplasia with Priority Review and a 4 February 2027 goal date. See the PROPEL 3 data and what happens next.
FDA accepts the oral infigratinib NDA for achondroplasia with Priority Review and a 4 February 2027 goal date. See the PROPEL 3 data and what happens next.